…
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
| Income before tax | -4.05M | -2.92M | -0.30M | -8.47M | -0.29M |
| Minority interest | 0.05M | 0.02M | 0.00M | - | - |
| Net income | -4.00M | -2.90M | -0.30M | -8.47M | -0.29M |
| Selling general administrative | 2.76M | 1.59M | 0.31M | 8.48M | 0.31M |
| Reconciled depreciation | 0.01M | 0.01M | 0.00M | - | - |
| Operating income | -4.37M | -2.92M | -0.31M | -8.48M | -0.31M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.00M | -0.00M | 0.00M | -0.00M | 0.00M |
| Total revenue | 0.00M | 0.01M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 4.37M | 2.92M | 0.31M | 8.48M | 0.31M |
| Total other income expense net | 0.32M | 0.00M | 0.01M | 0.01M | 0.02M |
| Net income from continuing ops | -4.05M | -2.92M | -0.30M | -8.47M | -0.29M |
| Breakdown | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
| Total assets | 75.46M | 70.25M | 1.81M | 0.06M | 0.25M |
| Intangible assets | 45.51M | 42.71M | 0.01M | 0.00M | - |
| Other current assets | 0.51M | 0.04M | - | 0.00M | 0.00M |
| Total liab | 11.23M | 10.38M | 0.03M | 0.03M | 0.05M |
| Total stockholder equity | 64.28M | 59.87M | 1.78M | 0.03M | 0.19M |
| Capital stock | 0.02M | 0.02M | 0.00M | 0.01M | 0.01M |
| Retained earnings | -50.79M | -46.78M | -43.88M | -42.20M | -33.73M |
| Good will | 27.16M | 25.49M | 0.00M | - | - |
| Cash | 0.02M | 0.02M | 0.05M | 0.01M | 0.25M |
| Total current liabilities | 1.17M | 1.06M | 0.03M | 0.03M | 0.05M |
| Net debt | 0.04M | - | - | 0.01M | - |
| Short long term debt | 0.06M | - | 0.01M | 0.01M | - |
| Total current assets | 0.53M | 0.06M | 0.05M | 0.05M | 0.25M |
| Long term investments | 2.25M | 1.93M | 1.75M | 0.00M | - |
| Net receivables | - | - | 0.00M | 0.04M | 0.00M |
| Accounts payable | 1.11M | 1.06M | 0.01M | 0.01M | 0.05M |
| Non currrent assets other | 0.00M | 0.06M | - | - | - |
| Non current assets total | 74.93M | 70.19M | 1.76M | 0.00M | 0.00M |
| Breakdown | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-08-31 | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
| Investments | - | 0.15M | 0.00M | - | - |
| Net borrowings | 0.06M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cash from financing activities | 4.34M | 1.08M | 0.31M | 0.13M | 0.40M |
| Net income | -4.00M | -2.90M | -0.30M | -8.47M | -0.29M |
| Change in cash | 0.00M | -0.06M | 0.05M | -0.24M | 0.12M |
| Begin period cash flow | 0.02M | 0.05M | 0.01M | 0.25M | 0.13M |
| End period cash flow | 0.02M | 0.02M | 0.05M | 0.01M | 0.25M |
| Total cash from operating activities | -4.32M | -1.28M | -0.26M | -0.37M | -0.28M |
| Issuance of capital stock | 4.35M | 0.19M | 0.00M | 0.00M | 0.40M |
| Depreciation | 0.01M | 0.01M | 0.00M | - | - |
| Dividends paid | - | 0.00M | 0.00M | 0.00M | - |
| Sale purchase of stock | -0.08M | 0.00M | - | - | - |
| Capital expenditures | 0.02M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.40M | 0.96M | 0.04M | -0.04M | 0.00M |
| Stock based compensation | 0.14M | 0.53M | 0.00M | 8.14M | 0.00M |
| Other non cash items | 0.31M | 0.14M | - | - | - |
| Free cash flow | -4.34M | -1.29M | -0.26M | -0.37M | -0.28M |
Sector: Industrials Industry: Consulting Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| NORD Nordicus Partners Corporation Common Stock |
-0.13 4.44% |
2.80 | - | - | 12107.93 | 1.18 | 16971.54 |
| EXPGF Experian PLC |
- -% |
37.51 | 26.59 | 19.34 | 4.43 | 6.44 | 4.99 |
| EXPGY Experian plc PK |
-0.97 2.59% |
36.53 | 26.45 | 19.30 | 4.41 | 6.43 | 4.99 |
| VRSK Verisk Analytics Inc |
1.71 0.85% |
202.23 | 28.72 | 21.88 | 7.52 | 74.89 | 9.06 |
| EFX Equifax Inc |
0.72 0.41% |
177.23 | 30.32 | 17.18 | 3.05 | 4.62 | 3.96 |
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
280 South Beverly Dr, Beverly Hills, CA, United States, 90212
310 666 0750
| Name | Title | Year Born |
|---|---|---|
| Mr. Henrik Rouf | CEO & President | 1968 |
| Mr. Bennett Jay Yankowitz | CFO & Director | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.